HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 [email protected]...

35
HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 [email protected] Adrenergic Agonists &Other Sympathomimetics

Transcript of HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 [email protected]...

Page 1: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

HuBio 543September 26, 2007

Neil M. NathansonK-536A, [email protected] Adrenergic Agonists &Other Sympathomimetics

Page 2: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

CLASSES OF SYMPATHOMIMETICS

Direct-acting Indirect-actingMixed-actingAlbuterolDobutamine DopamineEpinephrineFendolopamIsoproterenolNorepinephrinePhenylephrineRitodrineSalmeterolTerbutaline

Ephedrine

AmphetamineTyramine

Page 3: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

Reminder: Subtypes of Adrenergic Receptors

: EPI > NOR >>ISOß: ISO > EPI > NE

1: contraction of smooth muscle (incl. VSM)2: presynaptic receptors ( decrease NE release)ß1: in heart and juxtaglomerular cells (and some fat cells)ß2: relaxation of smooth muscle ß3: some fat cellsNOTE ON ß2: (1) mediate relaxation of skeletal muscle vasculature

(2) P’cologically administered NE is not effective

Page 4: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

EPINEPHRINE: MORE POTENT AT ß2 THAN AT 1

The Ugly Truth About Epinephrine

Therefore: you would predict that low doses of EPI preferentially activate ß2 receptors over 1 receptors

Low doses of EPI: preferentially activate ß2 receptors in skeletal muscle vasculature: cause vasodilation, leading to a decrease in total peripheral resistance (TPR)High doses of EPI: activate both ß2 and 1 receptors: 1 response predominates, resulting in vasoconstriction, which causes an increase in total peripheral resistance (TPR)

Page 5: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

Effects of Epinephrine on the Cardiovascular System

Drug Direct ReflexAction Effect Effect Result

Stimulateß-AdR

Increase rateand force -----

Cardiac output, HR, Systolic pressure

Stimulateß2-AdR(preferentiallyover 1-AdR)

Vaso-dilation --

---

TPR

Diastolic pressure

Page 6: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NE EPI ISO DA

Pulse rate

BP (mm. Hg)

60

120

180

50

100

Periphe

ral

Resista

nce

15 min15 min15 min

15 min

(10 µg/min) (10 µg/min) (10 µg/min) (0.5 µg/min)

Slow IV administration in humans

Page 7: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NEEPI ISO DA PHEN.

HR

BP

TPR

Effects of agonists on cardiovascular function (slow IV administration)

Page 8: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

QuickTime™ and aTIFF (LZW) decompressor

are needed to see this picture.

“In the Corner With the Gladiators: Trying Out the Life of the Cut Man” by Harry Hurt, III NYT, 8/26/07

Page 9: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

Necrosis Following Extravasation of Epinephrine

Page 10: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

Effects of Norepinephrine on the Cardiovascular System

Drug Direct ReflexAction Effect Effect Result

Stronglystimulateß-AdR

(Increase rateand force) HR

Cardiac output, HR,

Stimulate1-AdR

Vaso-constriction

TPR

Diastolic pressureSystolic pressure

Page 11: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NE EPI ISO DA

Pulse rate

BP (mm. Hg)

60

120

180

50

100

Periphe

ral

Resista

nce

15 min15 min15 min

15 min

(10 µg/min) (10 µg/min) (10 µg/min) (0.5 µg/min)

Slow IV administration in humans

Page 12: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NEEPI ISO DA PHEN.

HR

BP

TPR

Effects of agonists on cardiovascular function (slow IV administration)

Page 13: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

Effects of Isoproterenol on the Cardiovascular System

Drug Direct ReflexAction Effect Effect Result

Stimulateß-AdR

Increase rateand force

Cardiac output, HR, Systolic pressure

Stimulateß2-AdR

Much vaso-dilation --

---

TPR

Diastolic pressure

HR, Force

Page 14: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NE EPI ISO DA

Pulse rate

BP (mm. Hg)

60

120

180

50

100

Periphe

ral

Resista

nce

15 min15 min15 min

15 min

(10 µg/min) (10 µg/min) (10 µg/min) (0.5 µg/min)

Slow IV administration in humans

Page 15: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NEEPI ISO DA PHEN.

HR

BP

TPR

Effects of agonists on cardiovascular function (slow IV administration)

Page 16: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

DOPAMINE

D1 > ß > 1

Can activate: (1) vasodilatory dopamine (D1) receptors in renal, mesenteric, and coronary

vascular beds (2) beta receptors in heart

(greater effect on contractile force that rate)(3) stimulates NE release from

nerve terminals (contributes to

cardiac effects)(4) high doses can activate

vascular 1 receptors

Page 17: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.
Page 18: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NE EPI ISO DAPulse rate

BP (mm. Hg)

60

120

180

50

100

Periphe

ral

Resista

nce

15 min15 min15 min

15 min

(10 µg/min) (10 µg/min) (10 µg/min) (0.5 µg/min)

Page 19: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NEEPI ISO DA PHEN.

HR

BP

TPR

Effects of agonists on cardiovascular function (slow IV administration)

Page 20: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

Effects of Phenylephrine on the Cardiovascular System

Drug Direct ReflexAction Effect Effect Result

-------(No Effect)

(No Effect)HR HR

Stimulate1-AdR

Vaso-constriction

TPR

Diastolic pressureSystolic pressure

Page 21: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NEEPI ISO DA PHEN.

HR

BP

TPR

Effects of agonists on cardiovascular function (slow IV administration)

Page 22: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

200

50

BPmm Hg.

Symp.Nerve act.

VagusNerve act

HRbpm

100

40 0 1.0Time (min)

+ phenylephrine

Page 23: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

200

100

01200

1000

800

BP, mm Hg.

Pulse Interval (msec.)

30

20

10Sec after phenylephrine

120110 130 140

Systolic Pressure (mm Hg.)

Page 24: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

ß2- Adrenergic Agonists

AlbuterolRitodrineTerbutalineSalmeterol

Page 25: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

100

50

0

% reduction of intraluminal pressure%

increase in rate

% increase in force of contraction

Tracheal Muscle

Cardiac Muscle (Rate)

Cardiac Muscle (Force)

0.0001 0. 10. 01 100.001 1Concentration (µg/ml)

100

50

0

10050

0

ISO

ISO

ISO

ALB

ALB

ALB

Page 26: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

SALMETEROL

ALBUTEROL

PLACEBO

FIRST DOSE SECOND DOSE

0 3 6 9 12

FEV1

Time (Hours)

Time Course of Bronchodilation Produced by Albuterol and Salmeterol

Page 27: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

90

60

30

% Increase Over Basal

Value

10

50

30

10

ISOPROTERENOL

ALBUTEROL

Pulse Rate

FEV1.0

Pulse Rate

FEV1.0

DOSE (IV)

EFFECTS OF ISOPROTERENOL & ALBUTEROL IN HUMANS

Page 28: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

“ß1- Adrenergic Agonists”

One isomer is ß1 agonist and 1 agonistOther isomer is ß1 agonist (and apparently weak 1 antagonist) Increases contractile force, little effect on heart rate or TPRUsed to increase cardiac output (e.g., CHF)

Why does dobutamine have little effect on HR and TPR?

1. Human atria: 40- 50% ß1; human ventricle: 70- 85%ß1

2. Little or no ß2- mediated vasodilation, so no reflex tachycardia

3. 1 agonist activity may also contribute to direct stimulation of ventricles and lack of vasodilation

Dobutamine

Page 29: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

• Dopamine D1 receptor agonist

• IV administration causes rapid vasodilation

• Used for emergency management of severe hypertension

Fenoldopam

Page 30: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

400300200100040

90

140

190

IV Administration of Fenoldopam Patients with Postcardiac Surgery Hypertension

Time (minutes)

Pressure (mm Hg)

Heart Rate (bpm)

Diastolic BP

Heart Rate

Systolic BP

Page 31: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NE

NE

NE

Re-Up

NE

Indirect-acting sympathomimetics

NE NENENE

TYRAMINEAMPHETAMINE

Page 32: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

+ Tyramine + Norepinephrine

Pretreat with Cocaine:

Cocaine blocks vasopressor response to tyramine and potentiates response to norepinephrine

+ Norepinephrine+ Tyramine

BP

BP

Page 33: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

NE

NE

NE

Re-Up

NE

NENE

NE

NE

NE

Re-Up

NE

NE NENENE XNormal uptake of NE

NE uptake blocked by cocaine

Cocaine potentiates sympathetic transmission (and effects of NE

administration)

Page 34: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

BP (mm. Hg)

160

80

0

160

80

0

240

EPINEPHRINE

EPHEDRINE

Effects of epinephrine and ephedrine on blood pressure in dog

BP (mm. Hg)

Page 35: HuBio 543 September 26, 2007 Neil M. Nathanson K-536A, HSB 3-9457 nathanso@u.washington.edu Adrenergic Agonists &Other Sympathomimetics.

1 min.

EPHEDRINE TACHYPHYLAXIS IN THE DOG

Ephedrine (3 mg/kg) administered, every 10 min

BP